All‐cause mortality · people at increased risk for developing type 2 diabetes
It is very uncertain whether acarbose changes all‐cause mortality compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cardiovascular mortality · people at increased risk for developing type 2 diabetes
It is very uncertain whether acarbose changes cardiovascular mortality compared with no intervention (very low certainty).
1 finding from 1 review
(1) Non‐fatal myocardial infarction (2) Non‐fatal stroke (3) Congestive heart failure · people at increased risk for developing type 2 diabetes
It is very uncertain whether acarbose changes (a)Non‐fatal myocardial infarction (b)Non‐fatal stroke (c)Congestive… compared with no intervention (very low certainty).
1 finding from 1 review
Health‐related quality of life · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Socioeconomic effects · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Development of type 2 diabetes · people at increased risk for developing type 2 diabetes
Acarbose probably leads to lower incidence of T2DM compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · people at increased risk for developing type 2 diabetes
Acarbose showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Cardiovascular mortality · people at increased risk for developing type 2 diabetes
It is very uncertain whether acarbose changes cardiovascular mortality compared with placebo (very low certainty).
1 finding from 1 review
(1) Non‐fatal myocardial infarction (2) Non‐fatal stroke (3) Congestive heart failure · people at increased risk for developing type 2 diabetes
It is very uncertain whether acarbose changes (a)Non‐fatal myocardial infarction (b)Non‐fatal stroke (c)Congestive… compared with placebo (very low certainty).
1 finding from 1 review
Health‐related quality of life · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Socioeconomic effects · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · people at increased risk for developing type 2 diabetes
1 finding from 1 review
Development of type 2 diabetes · people at increased risk for developing type 2 diabetes
It is very uncertain whether acarbose changes incidence of T2DM compared with no intervention (very low certainty).
1 finding from 1 review
Acarbose · people at increased risk for developing type 2 diabetes
2 findings from 1 review
Acarbose Diagnostic criteria: 1 study applied the WHO 1999 criteria for prediabetes (FPG > 6.1 mmol/L and < 7.0 mmol/L and/or a 2‐h glucose < 11.1 mmol/L after a 75 g OGTT; Chen 2007a) · people at increased risk for developing type 2 diabetes
1 finding from 1 review
Acarbose · people at increased risk for developing type 2 diabetes
3 findings from 1 review
Acarbose Diagnostic criteria: 1 trial applied the WHO 1985 criteria (FPG < 7.8 mmol/L and 2‐hour glucose ≥ 7.8 mmol/L and < 11.1 mmol/L) (Fang 2004). 1 trial applied the WHO 1999 criteria (FPG ≥ 7.0 mmol/L and/or a 2‐hpur glucose ≥ 11.1 mmol/L aft... · people at increased risk for developing type 2 diabetes
Summary of findings table for metformin showed no clear difference in acarbose Diagnostic criteria: 1 trial applied the WHO 1985 criteria… compared with diet and exercise or another antidiabetic drug (low certainty).
1 finding from 1 review
Hypertensive disorders of pregnancy ‐ not reported · women diagnosed with gestational diabetes; 11 to 33 weeks' gestation; singleton pregnancy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Caesarean section · women diagnosed with gestational diabetes; 11 to 33 weeks' gestation; singleton pregnancy
Glibenclamide showed no clear difference in caesarean section compared with acarbose ‐ maternal outcomes (low certainty).
1 finding from 1 review